By Josh White
Date: Tuesday 20 Jan 2026
(Sharecast News) - Niox Group reported a strong financial performance for 2025 on Tuesday, with revenue and earnings ahead of market expectations, as the medical device group benefited from robust demand across its clinical and research businesses and successfully launched its next-generation Niox PRO device.
| Total Voting Rights | 31-Dec-2025 | ShareCast |
| Niox reports strong first-half trading | 08-Jul-2025 | ShareCast |
| Niox Group reports strong start to 2025 | 14-May-2025 | ShareCast |
| Niox ends sale process as Keensight steps back | 11-Apr-2025 | ShareCast |
| Niox reports solid set of full-year results | 01-Apr-2025 | ShareCast |
| Grant of Options | 09-Apr-2026 | 13:55 | RNS |
| Director/PDMR Shareholding and Total Voting Rights | 01-Apr-2026 | 07:00 | RNS |
| Holding(s) in Company | 24-Mar-2026 | 15:22 | RNS |
| Final Results | 24-Mar-2026 | 07:00 | RNS |
| Block Listing Application | 16-Mar-2026 | 16:30 | RNS |
| Circassia raises £200m in landmark biotech IPO | 14-Mar-2014 | The Independent |
| Cat allergy group raises £200m in float | 14-Mar-2014 | Telegraph |
No recent information was found.
No recent information was found.
| Currency | UK Pounds |
| Share Price | 58.60p |
| Change Today | 0.60p |
| % Change | 1.03 % |
| 52 Week High | 76.00 |
| 52 Week Low | 54.40 |
| Volume | 80,335 |
| Shares Issued | 417.94m |
| Market Cap | £244.91m |
| Beta | 0.00 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 3 |
| Buy | 2 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 5 |

| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 15-May-25 | 23-May-24 |
| Paid | 16-Jun-25 | 24-Jun-24 |
| Amount | 1.25p | 1.00p |
| Time | Volume / Share Price |
| 14:08 | 7,840 @ 57.34p |
| 14:07 | 36 @ 57.32p |
| 13:50 | 382 @ 58.60p |
| 13:50 | 382 @ 58.60p |
| 13:50 | 1,755 @ 58.00p |
You are here: research